MiR-34a inhibitor protects mesenchymal stem cells from hyperglycaemic injury through the activation of the SIRT1/FoxO3a autophagy pathway

BACKGROUND: Mesenchymal stem cells (MSCs) are favourable treatments for ischaemic diseases; however, MSCs from diabetic patients are not useful for this purpose. Recent studies have shown that the expression of miR-34a is significantly increased in patients with hyperglycaemia; the precise role of m...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Fengyun, Gao, Fei, Wang, Kun, Liu, Xiaohong, Zhang, Zhuoqi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7866658/
https://www.ncbi.nlm.nih.gov/pubmed/33546760
http://dx.doi.org/10.1186/s13287-021-02183-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7866658/
https://www.ncbi.nlm.nih.gov/pubmed/33546760
http://dx.doi.org/10.1186/s13287-021-02183-2

Ejemplares similares